Bribery allegations hang over Biomet/Zimmer; FDA clears 31 digital health apps in 2014;

> Bribery allegations in Brazil and Mexico hang over Biomet, tainting its acquisition by Zimmer ($ZMH). The New York Times details the background and how regulators might address them to allow the deal to go forward. Story

> Interleukin Genetics raised $10 million, half in debt and half in equity, to market its genetic tests including one to determine predisposition to severe periodontal disease. The debt is from Horizon Technology Finance ($HRZN), while the equity it from New Enterprise Associates and Bay City Capital. Release

> Sinus dilation player Entellus Medical filed to raise up to $69 million in a public offering, but coronary artery disease test maker CardioDx withdrew its IPO after securing $35M in private financing earlier this week.

> Mobihealthnews has a roundup and analysis of all 31 digital health apps cleared by FDA in 2014. More

> India will now allow foreign companies to acquire India-based medical device companies. Story

> Corgenix Medical ($CONX) received two grants for a total of $818,000 for the development of an Ebola rapid diagnostic kit from the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation. Release